InsiderSignal.AI

InsiderSignal.ai

RXRX - Recursion Pharmaceuticals, Inc.

Insider Sale by Khan Najat (CEO, Pres)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

6 days ago, Khan Najat, serving as CEO, Pres at Recursion Pharmaceuticals, Inc. (RXRX), sold 28,298 shares at $3.35 per share, for a total transaction value of $94,660.00. Following this transaction, Khan Najat now holds 2,262,085 shares of RXRX.

This sale represents a 1.00% decrease in Khan Najat's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Monday, March 9, 2026 and publicly disclosed via SEC Form 4 filing on Wednesday, March 11, 2026, 2 days after the trade was made.

Recursion Pharmaceuticals, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Khan Najat

CEO, Pres

Najat Khan, Ph.D. is the Chief Executive Officer, President, and Board Member of Recursion Pharmaceuticals, Inc. (RXRX), a clinical-stage TechBio company, effective January 1, 2026. She joined Recursion in April 2024 as a Board Member and became Chief Research and Development Officer and Chief Commercial Officer in July 2024, where she advanced the company's AI-native drug discovery pipeline in oncology, rare disease, neuroscience, and immunology, led the 2024 combination with Exscientia, and expanded the Recursion OS 2.0 platform.[[1]](https://www.nasdaq.com/articles/recursion-pharma-appoints-najat-khan-ceo)[[2]](https://www.recursion.com/team-members/najat-khan)[[3]](https://www.sec.gov/Archives/edgar/data/1601830/000160183025000164/rxrx-20251104.htm)[[5]](https://www.statnews.com/2025/11/05/recursion-ceo-chris-gibson-out-najat-khan-new-head/) Prior to Recursion, Dr. Khan served as Chief Data Science Officer and Senior Vice President, Global Head of Strategy, Portfolio & Operations for R&D at Johnson & Johnson Innovative Medicine from June 2023 to June 2024, tripling pipeline value, advancing 10 potential blockbusters, and scaling AI across R&D as Co-chair of the Data Science Council.[[2]](https://www.recursion.com/team-members/najat-khan)[[3]](https://www.sec.gov/Archives/edgar/data/1601830/000160183025000164/rxrx-20251104.htm)[[4]](https://jclinic.mit.edu/team-member/najat-khan/) Earlier, she was a Senior Principal and Partner at The Boston Consulting Group, advising biopharma and biotech clients. Dr. Khan holds a Ph.D. in Organic Chemistry from the University of Pennsylvania, an AI/ML Certification from MIT’s CSAIL, and a B.A. in Computational Chemistry from Colgate University. She is active in industry consortia like DISRUPT and serves on the board of the Alliance for Artificial Intelligence in Healthcare.[[2]](https://www.recursion.com/team-members/najat-khan)[[3]](https://www.sec.gov/Archives/edgar/data/1601830/000160183025000164/rxrx-20251104.htm)

View full insider profile →

Trade Price

$3.35

Quantity

28,298

Total Value

$94,660.00

Shares Owned

2,262,085

Trade Date

Monday, March 9, 2026

6 days ago

SEC Filing Date

Wednesday, March 11, 2026

Filed 2 days after trade

HEALTHCAREBIOTECHNOLOGY

About Recursion Pharmaceuticals, Inc.

Company Overview

No company information available
View news mentioning RXRX

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/4697670

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime